| ID Source | ID |
|---|---|
| PubMed CID | 4369491 |
| CHEMBL ID | 214253 |
| SCHEMBL ID | 6516584 |
| MeSH ID | M0540485 |
| Synonym |
|---|
| HMS3269N21 |
| BRD-K82823804-001-01-7 |
| 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione |
| DB04608 |
| 9-hydroxy-4-phenyl-6h-pyrrolo[3,4-c]carbazole-1,3-dione |
| NCGC00167836-01 |
| bdbm50192349 |
| CHEMBL214253 , |
| pd-407824 |
| HMS3262B15 |
| FT-0673544 |
| pd 407824 |
| 622864-54-4 |
| CCG-222111 |
| pd407824 |
| NCGC00261492-01 |
| tox21_500807 |
| IAUZTOZLTFSMIE-UHFFFAOYSA-N , |
| SCHEMBL6516584 |
| 9-hydroxy-4-phenyl-pyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione |
| pd0407824 |
| AKOS024457242 |
| DTXSID40402483 |
| pd-407824, >=98% (hplc) |
| '9-hydroxy-4-phenyl-6h-pyrrolo[3,4-c]carbazole-1,3-dione' |
| HY-18961 |
| CS-0014679 |
| HMS3677B22 |
| Q27095347 |
| HMS3413B22 |
| NCGC00167836-04 |
| MS-24916 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 22.3872 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 28.1838 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 25.0594 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 28.1838 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 31.6228 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 4.4668 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 4.2328 | 0.0015 | 30.6073 | 15,848.9004 | AID1224819; AID1224820; AID1224821 |
| polyprotein | Zika virus | Potency | 4.4668 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | IC50 (µMol) | 0.0470 | 0.0001 | 0.4530 | 8.8300 | AID268839; AID320854; AID363040 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 1.1701 | 10.0000 | AID268846 |
| Protein kinase C gamma type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 1.0354 | 10.0000 | AID268846 |
| Protein kinase C beta type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.5542 | 10.0000 | AID268846 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0006 | 0.8007 | 8.5000 | AID268841 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0002 | 0.9420 | 10.0000 | AID268842 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | IC50 (µMol) | 3.7500 | 0.0006 | 0.5706 | 10.0000 | AID268843 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0002 | 0.5335 | 10.0000 | AID268840 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0001 | 0.4912 | 10.0000 | AID268841 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.9720 | 10.0000 | AID268846 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0004 | 0.3276 | 8.6200 | AID268842 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0008 | 0.6217 | 8.6200 | AID268842 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0004 | 0.2863 | 8.6200 | AID268842 |
| Protein kinase C eta type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.7971 | 10.0000 | AID268846 |
| Wee1-like protein kinase | Homo sapiens (human) | IC50 (µMol) | 0.0971 | 0.0039 | 0.0597 | 0.1650 | AID268838; AID320853; AID363039; AID374098 |
| Protein kinase C iota type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 2.0378 | 10.0000 | AID268846 |
| Protein kinase C epsilon type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.8029 | 10.0000 | AID268846 |
| Peptidyl-prolyl cis-trans isomerase FKBP4 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0160 | 5.1287 | 8.0000 | AID268841; AID268842 |
| Protein kinase C theta type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.9897 | 10.0000 | AID268846 |
| Protein kinase C zeta type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 2.4453 | 10.0000 | AID268846 |
| Protein kinase C delta type | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 0.8448 | 10.0000 | AID268846 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0001 | 1.2319 | 10.0000 | AID268846 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||